ArticleFrontiers in aging neuroscience2025
Relationship between cerebrospinal fluid circulation markers, brain degeneration, and cognitive impairment in cerebral amyloid angiopathy.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluating Basigin as a Potential Biomarker of Blood-Brain Barrier Dysfunction in Cerebral Amyloid Angiopathy.Neuropathology and applied neurobiology · 2026Article
- Reconsideration of the DTI-ALPS index as a glymphatic surrogate: disease-specific findings in small vessel disease due to cerebral amyloid angiopathy or arteriolosclerosis.Frontiers in aging neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate whether cerebrospinal fluid (CSF) circulation markers alter in patients with probable cerebral amyloid angiopathy (pCAA) and whether they are associated with brain degeneration and cognitive impairment. Methods: We screened pCAA patients from the ADNI3 database according to the Boston 2.0 Criteria. Fifty-two patients with cognitive impairment (26 pCAA; 26 age-sex-matched non-pCAA) and 26 age-sex-matched cognitively normal control (NC) were included in this study. All participants underwent neurological MRI and cognitive assessments. Choroid plexus (ChP) was segmented using a deep learning-based method and its volume was extracted. Diffusion tensor imaging analysis along the perivascular space (DTI-ALPS) was used to assess perivenous fluid mobility. AD pathological markers (Aβ and tau) were assessed using positron emission tomography. Brain parenchymal damage markers included white matter hyperintensities (WMH) volume and brain atrophy ratio. All markers were compared among the three groups. Correlations among the ChP volume, DTI-ALPS index, parenchymal damage markers, and cognitive scales were analyzed in the pCAA group. Results: The three groups exhibited significant differences in cognitive scores, AD biomarkers, and imaging markers. Conclusion: CSF circulation markers were associated with elevated WMH burden and cognitive impairments in probable CAA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.